Neuronetics, Inc. Announces Departure Of CFO Steven E. Pfanstiel, Transition To Continue Through May 2026

Neuronetics, Inc., a medical technology company focused on developing and commercializing products that improve the lives of patients with neurohealth disorders—and the maker of NeuroStar® Advanced Therapy NeuroStar Advanced Therapy—announced that Steven E. Pfanstiel will be leaving his position as Executive Vice President, Chief Financial Officer, and Treasurer. He has chosen to pursue an opportunity outside the Company. To ensure continuity, he will continue in his role until May 1, 2026, supporting a smooth and orderly transition.

The Company confirmed that Mr. Pfanstiel’s decision to resign is not related to any disagreement with Neuronetics, its leadership, or its Board of Directors regarding the Company’s operations, policies, or business practices. Neuronetics has begun a formal search to identify and appoint his successor.

Alongside this leadership update, the Company reaffirmed the financial guidance it previously shared during its fourth quarter 2025 earnings call on March 17, 2026. This reaffirmation reflects Neuronetics’ confidence in its current operational performance and ongoing business priorities as it moves forward with its transition planning.